Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium
January 14, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
January 12, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million
August 26, 2020 22:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
August 06, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing – – Merck collaboration to discover and develop influenza A/B antiviralagents progresses – ...
Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors
April 20, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...
Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit
April 15, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session – BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market
March 09, 2020 15:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Plans to Advance Coronavirus Program
March 06, 2020 16:01 ET
|
Cocrystal Pharma, Inc.
Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
February 28, 2020 14:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Announces $11.0 Million Registered Direct Offering Priced At-the-Market
February 27, 2020 07:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...